Valve Replacement

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 128451 Experts worldwide ranked by ideXlab platform

Anson Cheung - One of the best experts on this subject based on the ideXlab platform.

  • Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement
    Circulation. Cardiovascular interventions, 2018
    Co-Authors: Anson Cheung, John Webb, Ulrich Schaefer, Robert Moss, Florian Deuschl, Lenard Conradi, Paolo Denti, Azeem Latib, Bob Kiaii, Rodrigo Bagur
    Abstract:

    Background: Transcatheter mitral Valve Replacement (TMVR) may mature to become a therapeutic option for high-risk patients with severe mitral regurgitation (MR), particularly in patients at high or...

  • Transcatheter Aortic Valve Replacement
    Anesthesiology Clinics, 2008
    Co-Authors: Anson Cheung, Ron Ree
    Abstract:

    Aortic stenosis is one of the most common Valve pathologies found in adults. Aortic Valve Replacement via a sternotomy and cardiopulmonary bypass is the treatment of choice for patients with symptomatic aortic stenosis with very acceptable risk. However, patients with advanced age and multiple comorbidities carry significant operative risk; operative mortality as high as 25% was reported by many groups. Many of these patients are deemed nonsurgical for conventional aortic Valve Replacement by their cardiologists and surgeons. Novel surgical technique and Valve technology offers an alternative treatment for aortic Valve stenosis. Endovascular transcatheter aortic Valve Replacement is an emerging and promising technique, and may lower the risk in this subset of difficult patients. © 2008 Elsevier Inc. All rights reserved.

  • Transcatheter Aortic Valve Replacement
    Anesthesiology clinics, 2008
    Co-Authors: Anson Cheung, Ron Ree
    Abstract:

    Aortic stenosis is one of the most common Valve pathologies found in adults. Aortic Valve Replacement via a sternotomy and cardiopulmonary bypass is the treatment of choice for patients with symptomatic aortic stenosis with very acceptable risk. However, patients with advanced age and multiple comorbidities carry significant operative risk; operative mortality as high as 25% was reported by many groups. Many of these patients are deemed nonsurgical for conventional aortic Valve Replacement by their cardiologists and surgeons. Novel surgical technique and Valve technology offers an alternative treatment for aortic Valve stenosis. Endovascular transcatheter aortic Valve Replacement is an emerging and promising technique, and may lower the risk in this subset of difficult patients.

Ron Ree - One of the best experts on this subject based on the ideXlab platform.

  • Transcatheter Aortic Valve Replacement
    Anesthesiology Clinics, 2008
    Co-Authors: Anson Cheung, Ron Ree
    Abstract:

    Aortic stenosis is one of the most common Valve pathologies found in adults. Aortic Valve Replacement via a sternotomy and cardiopulmonary bypass is the treatment of choice for patients with symptomatic aortic stenosis with very acceptable risk. However, patients with advanced age and multiple comorbidities carry significant operative risk; operative mortality as high as 25% was reported by many groups. Many of these patients are deemed nonsurgical for conventional aortic Valve Replacement by their cardiologists and surgeons. Novel surgical technique and Valve technology offers an alternative treatment for aortic Valve stenosis. Endovascular transcatheter aortic Valve Replacement is an emerging and promising technique, and may lower the risk in this subset of difficult patients. © 2008 Elsevier Inc. All rights reserved.

  • Transcatheter Aortic Valve Replacement
    Anesthesiology clinics, 2008
    Co-Authors: Anson Cheung, Ron Ree
    Abstract:

    Aortic stenosis is one of the most common Valve pathologies found in adults. Aortic Valve Replacement via a sternotomy and cardiopulmonary bypass is the treatment of choice for patients with symptomatic aortic stenosis with very acceptable risk. However, patients with advanced age and multiple comorbidities carry significant operative risk; operative mortality as high as 25% was reported by many groups. Many of these patients are deemed nonsurgical for conventional aortic Valve Replacement by their cardiologists and surgeons. Novel surgical technique and Valve technology offers an alternative treatment for aortic Valve stenosis. Endovascular transcatheter aortic Valve Replacement is an emerging and promising technique, and may lower the risk in this subset of difficult patients.

Michael J. Reardon - One of the best experts on this subject based on the ideXlab platform.

  • computed tomography based indexed aortic annulus size to predict prosthesis patient mismatch transcatheter aortic Valve Replacement versus surgical aortic Valve Replacement in the surtavi trial
    Circulation-cardiovascular Interventions, 2019
    Co-Authors: Stuart J Head, Michael J. Reardon, Michael G Deeb, Nicolas M Van Mieghem, Jeffrey J Popma, Thomas G Gleason, Mathew R Williams, Sam Radhakrishnan, Stephen E Fremes, Yanping Chang
    Abstract:

    Background: Hemodynamic performance of prostheses after transcatheter aortic Valve Replacement (TAVR) is generally better than after surgical aortic Valve Replacement (SAVR), especially in patients...

  • Complexities of transcatheter mitral Valve Replacement (TMVR) and why it is not transcatheter aortic Valve Replacement (TAVR).
    Annals of cardiothoracic surgery, 2018
    Co-Authors: Moritz C. Wyler Von Ballmoos, Ankur Kalra, Michael J. Reardon
    Abstract:

    Transcatheter mitral Valve Replacement (TMVR) is currently being investigated as a procedural alternative to surgical mitral Valve repair or Replacement (SMVR). Early data from first-in-man trials with current devices suggest that TMVR is technically feasible but carries a high mortality. This is substantially different from the early success transcatheter aortic Valve Replacement (TAVR) has seen and is related to complexities of the mitral Valve anatomy, differences in pathology that require mitral Valve Replacement as well as the impact that mitral Valve Replacement has on physiology and cardiac function, irrespective of the modality by which the mitral Valve is replaced. Importantly, in the case of TAVR, a less invasive method is offered to accomplish the same as the traditional surgical intervention. On the other hand, Valve Replacement is not the recommended treatment option for the majority of mitral Valve disease, and in fact is avoided whenever possible during surgery given the shortened life expectancy and increased morbidity with mitral Valve Replacement. Another distinction between TAVR and TMVR is the etiology and natural progression of the underlying disease and driving factors for intervention that are vastly different between aortic and mitral Valve disease. The primary aortic disease treated has been aortic stenosis, which has several etiologic factors that cause a similar physiologic dysfunction and risk. Aortic Valve Replacement leads to improved survival and quality of life. The primary mitral Valve disease targeted is regurgitation, which occurs as a primary Valve defect and as a secondary consequence of ventricular dysfunction. Primary mitral regurgitation is treated by Valve repair with excellent long-term outcomes. Secondary regurgitation has poor long-term outcomes with current commonly used repair techniques and limited data exists showing that correction of the regurgitation improves survival. Adoption of TMVR will require overcoming the anatomic challenges as well as generating data that supports improved survival and/or quality of life.

  • Allograft Valves for aortic and mitral Valve Replacement.
    Current opinion in cardiology, 1997
    Co-Authors: Michael J. Reardon, Mark F. O'brien
    Abstract:

    Allograft Valves have been used in cardiac Valve Replacement for 35 years. During much of this time, certain centers have used allograft aortic Valves for aortic Valve Replacement and have reported excellent long-term results. After an initial period of failure using allograft mitral Valves for mitral Valve Replacement, the technical problems of papillary muscle dehiscence and mitral regurgitation appear minimized by current investigators who now report encouraging early results. The current status of allograft use for aortic and mitral Valve Replacement is reviewed.

John P. Vavalle - One of the best experts on this subject based on the ideXlab platform.

Alan W. Heldman - One of the best experts on this subject based on the ideXlab platform.

Related terms

Valve Replacement - 15 days free trial to Access Experts & Abstracts